Journal: JAMA Network Open

Article Title: Newborn Screening for High-Risk Congenital Heart Disease by Dried Blood Spot Biomarker Analysis

doi: 10.1001/jamanetworkopen.2024.18097

Figure Lengend Snippet: CHD indicates congenital heart disease; IL-1 RL1, interleukin 1 receptor-like 1; NT-proBNP, amino-terminal prohormone of brain natriuretic peptide; ROC, receiver operating curve. Panels A through C include 188 cases and 97 controls (AUC = 0.95; 95% CI, 0.93-0.98). Panels D through F include 70 cases and 86 controls (AUC = 0.97; 95% CI, 0.94-0.99). In panels B, C, E, and F, black bars represent the median; boxes, IQR; whiskers, 95% CIs; dots, outliers.

Article Snippet: We coated microtitration strips with 96-well format (ThermoFisher Scientific) with either monoclonal anti–NT-proBNP antibody (HyTest Ltd) or anti–IL-1 RL1 antibody (Medix Biochemica) and labeled monoclonal tracer antibodies (HyTest Ltd for NT-proBNP; Medix Biochemica for IL-1 RL1) with Europium chelate (Eu).

Techniques:

Journal: JAMA Network Open

Article Title: Newborn Screening for High-Risk Congenital Heart Disease by Dried Blood Spot Biomarker Analysis

doi: 10.1001/jamanetworkopen.2024.18097

Figure Lengend Snippet: CHD indicates congenital heart disease; IL-1 RL1, interleukin 1 receptor-like 1; NT-proBNP, amino-terminal prohormone of brain natriuretic peptide.

Article Snippet: We coated microtitration strips with 96-well format (ThermoFisher Scientific) with either monoclonal anti–NT-proBNP antibody (HyTest Ltd) or anti–IL-1 RL1 antibody (Medix Biochemica) and labeled monoclonal tracer antibodies (HyTest Ltd for NT-proBNP; Medix Biochemica for IL-1 RL1) with Europium chelate (Eu).

Techniques:

Journal: medRxiv

Article Title: Rapid antifouling nanocomposite coating enables highly sensitive multiplexed electrochemical detection of myocardial infarction and concussion markers

doi: 10.1101/2021.06.13.21258856

Figure Lengend Snippet: Schematic and Calibration curves for different biomarkers of Myocardial infarction and Traumatic Brain Injury using antifouling nanocomposite coated EC Biosensors and ELISA. a, Schematic for the preparation and assay steps for the EC Biosensor. b-g, Calibration curves for different biomarkers. Left y-axis shows current density for different concentrations of biomarkers run on EC biosensors (red circle) using unprocessed human plasma while right y-axis shows mean absorbance (a.u) for different concentration of biomarkers run in ELISA plate using plasma (black triangle). Different biomarkers tested include b, cardiac troponin I (cTnI); n=6, c, cardiac troponin ITC complex (cTnI-TC); n=5, d, B-type natriuretic peptide (BNP); n=4, e, N-terminal (NT)-pro hormone BNP (NT-proBNP); n=4, f, Glial fibrillary acidic protein (GFAP); n=3, and g, S100b protein; n=3. Error bars represent the s.d. of the mean; n=2 for all ELISA assay. Analysis was done using 4-Parameter Logistic (4PL) curve fitting. Lowest concentration showing significant difference against background (0 ng/mL) was determined by unpaired t -test ( ns P > 0 . 05; * P < 0.05; ** P < 0.01 *** P < 0.001; **** P < 0.0001; all two tailed.

Article Snippet: Antigen includes [cTnI (Medix Biochemica, no. 610102), cTnI-TC complex (HyTest, no. 8T62), NT-proBNP (Medix Biochemica, no. 610090), BNP-32 (Bachem, no. 4095916), GFAP (HyTest, no. 8G45), and S100b (HyTest, no. 8S9h)], respectively.

Techniques: Enzyme-linked Immunosorbent Assay, Concentration Assay, Two Tailed Test

Journal: medRxiv

Article Title: Biofabrication of multiplexed electrochemical immunosensors for simultaneous detection of clinical biomarkers in complex fluids

doi: 10.1101/2022.03.18.22272576

Figure Lengend Snippet: Specificity and cross-reactivity test for different biomarkers of Myocardial Infarction (MI) and Traumatic Brain Injury (TBI) done in 96 well plate. a) Specificity and cross-reactivity of NT-proBNP antigen against different non-specific capture and detection antibodies (anti-cTnITC, anti-BNP, anti-GFAP, and anti-S-100b) along with specific detection with anti-NT-proBNP capture and detection antibody at different concentrations of NT-proBNP. b) Specificity and cross-reactivity of BNP antigen against different non-specific capture and detection antibodies along with specific detection with anti-BNP capture and detection antibody at different concentrations of BNP. c) Specificity and cross-reactivity of GFAP antigen against different non-specific capture and detection antibodies along with specific detection with GFAP capture and detection antibody at different concentrations of GFAP. d) Specificity and cross-reactivity of S-100b antigen against different non-specific capture and detection antibodies along with specific detection with S-100b capture and detection antibody at different concentrations of GFAP.

Article Snippet: Detection antibodies used for the assay include anti-BNP (HyTest, no. 24C5cc), anti-NT-proBNP (Medix Biochemica, no. 100 712), anti-cTnI (Abcam, no. ab243982), anticTnI-TC (Advanced ImmunoChemical, USA no. 2-TC), anti-GFAP (HyTest, no. GFAP81cc), anti-S-100b (HyTest, no. 6G1cc), anti NF-L (Uman Diagnostics, no. 27018), anti-IL-6, anti-IL-8, anti-IL-18, anti-VEGF, and anti-Ag85-B, respectively.

Techniques:

Journal: medRxiv

Article Title: Biofabrication of multiplexed electrochemical immunosensors for simultaneous detection of clinical biomarkers in complex fluids

doi: 10.1101/2022.03.18.22272576

Figure Lengend Snippet: Specificity and Multiplexed detection for different biomarkers of MI and TBI using antifouling nanocomposite coated EC Biosensors. a) Calibration curve for multiplex detection of cTnITC using plasma sample on the EC Biosensor with four different capture antibodies on each electrode (anti-cTnITC, anti-S-100b, anti-GFAP, and anti-NT-proBNP). b) Calibration curve for multiplex detection of increasing concentration of cTnITC (left y-axis) and decreasing concentration of GFAP (right y-axis) using plasma sample (c) and whole blood (d) on the EC Biosensor with four different capture antibodies on each electrode. e) Calibration curve for multiplex detection of increasing concentration of s100 (left y-axis) and decreasing concentration of GFAP (right y-axis) using whole blood on the EC Biosensor with four different capture antibodies on each electrode. Error bars represent the s.d. of the mean; n = 3.

Article Snippet: Detection antibodies used for the assay include anti-BNP (HyTest, no. 24C5cc), anti-NT-proBNP (Medix Biochemica, no. 100 712), anti-cTnI (Abcam, no. ab243982), anticTnI-TC (Advanced ImmunoChemical, USA no. 2-TC), anti-GFAP (HyTest, no. GFAP81cc), anti-S-100b (HyTest, no. 6G1cc), anti NF-L (Uman Diagnostics, no. 27018), anti-IL-6, anti-IL-8, anti-IL-18, anti-VEGF, and anti-Ag85-B, respectively.

Techniques: Multiplex Assay, Concentration Assay

Journal: Frontiers in Cardiovascular Medicine

Article Title: A swine model of severe chronic thromboembolic pulmonary hypertension induced by repeated pulmonary artery long suture injection

doi: 10.3389/fcvm.2025.1736958

Figure Lengend Snippet: Right ventricular myocardium gene expression (A) and protein levels (B) , and circulating plasma mediator levels (C) in chronic thromboembolic pulmonary hypertension (CTEPH) and sham (sham). Gene expression data depicts genes involved in myofilament remodeling (MYH6 and MYH7, α- and β-myosin heavy chain isoforms, respectively), extracellular matrix fibrosis (COL1A1 and COL3A1, type I and III collagen chains, respectively), Ca 2+ -handling (ATP2A2, sarcoendoplasmic reticulum calcium ATPase 2; RYR2, cardiac ryanodine receptor), and neurohumoral mediators (NPPB, B-type natriuretic peptide; EDN1, endothelin-1; TNF, tumor necrosis factor-α). Data were averaged upon normalization for 2 internal control genes, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and RPL4 (ribosomal protein L4). Calcium-handling protein levels of sarcoendoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) normalized for GAPDH and phospho-phospholamban (PLB) normalized for total PLB and representative Western blot bands are presented in (B) , whilst mediator plasma levels of N-terminal pro–B-type natriuretic peptide (NT-proBNP) and endothelin-1 (ET-1) are presented in panel C. In panels A and B data are presented relative to Sham reference levels (dashed lines). * P < 0.05 vs. Sham by Student's t -test or Mann–Whitney U -test, according to assumptions ( n = 6 and 7 in Sham and CTEPH, respectively).

Article Snippet: Previously aliquoted plasma samples were thawed on ice and assayed for N-terminal pro–B-type natriuretic peptide (NT-proBNP; CSB-EQ027465PI, Cusabio) and endothelin-1 (ET-1; ADI-900-020A, Enzo Life Sciences Inc) in duplicate according to the manufacturer's instructions.

Techniques: Gene Expression, Clinical Proteomics, Control, Western Blot, MANN-WHITNEY